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Glutamatergic-Dopaminergic Balance in the Brain 
Its importance in motor disorders and schizophrenia 
P. Riederer 3, K . W. Lange a, J. Kornhuber3, and W. Danielczyk b 
Summary 
Dopamine appears to be of less importance in the regu-
lation of psychomotor functions than was previously 
thought. A central dopaminergic-glutamatergic balance 
may be important for both akinetic motor disorders and 
psychosis. In Parkinson's disease glutamate antagonists 
may counteract central glutamatergic hyperactivity and 
may be of value as anti-parkinsonian drugs. An increase 
of dopaminergic activity and/or a reduction of glutama-
tergic activity may contribute to the development of par-
anoid hallucinatory psychosis in schizophrenic patients 
and of pharmacotoxic psychosis in Parkinson s disease. 
Because of possibly severe side-effects ofglutamatergic an-
tagonists and agonists in the treatment of akinesia and 
psychosis, the development ot partial glutamate agonists/ 
antagonists could be an alternative strategy capable of 
producing antipsychotic or anti-kinetic effects with only 
mild adverse reaction. 
Zusammenfassung 
Gleichgewicht zwischen zentralen glutaminergen und do-
paminergen Mechanismen / Relevanz fur Bewegungssto-
rungen und Schizophrenic 
Dopamin scheint von geringerer Bedeutung fur die Steue-
rung psychomotorischer Funktionen zu sein als man bis-
her angenommen hat. Ein Gleichgewicht zwischen do-
paminergen und glutamatergen Mechanismen ist mog-
licherweise sowohl fur akinetische Bewegungsstdrungen 
als auch fur Psychosen bedeutsam. Beim Morbus Parkin-
son konnten Glutamat-Antagonist en einer glutamatergen 
Uberaktivitat im Gehirn entgegenwirken und als Medi-
kamente wirksam sein. Eine erhohte dopaminerge Akti-
vitdt und/oder eine verminderte glutamaterge Aktivitat 
konnen zur Entwicklung von paranoid-halluzinatorischen 
Psychosen bei Schizophrenen und von pharmakotoxischen 
Psychosen bei Parkinson-Patienten beitragen. Wegen 
moglicherweise schwerwiegender Nebenwirkungen von 
Glutamat-Antagonisten und -Agonisten bei der Behand-
lung von Akinesie und Psychose konnte die Entwicklung 
von partiellen Glutamat-Agonisten und-Antagonisten eine 
alternative Therapiestrategie darstellen, die antipsycho-
tische und antikinetische Wirkungen mit nurgeringen Ne-
benwirkungen erzielt. 
Key words: Brain, chemical information transmission, glutamatergic-dopaminergic balance • Dopamine • 
Glutamate • Parkinson's disease • Psychosis, pharmacotoxic • Schizophrenia 
1. Dopamine and Parkinson's disease 
The loss of dopamine in the striatum as a result of the 
neuronal degeneration in the substantia nigra pars com-
pacta has been thought to be the major pathochemical 
correlate of the main symptoms of Parkinson's disease 
such as akinesia and rigidity (Ehringer and Hornykiewicz 
1960). The discovery of dopaminergic deficiency in the 
basal ganglia led to the use of replacement therapies in-
cluding L-dopa (levodopa) treatment (Birkmayer and 
Hornykiewicz 1961), dopaminergic agonists such as 
bromocriptine (Calne et al. 1974) and lisuride (Frieling 
1988), and the selective monoamine oxidase B inhibitor 
L-deprenyl (Birkmayer et al. 1975). These therapeutic 
strategies can improve the parkinsonian symptoms either 
alone or in combination with one another for a period of 
time. They are, however, unable to check the progression 
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of the nigrostriatal degeneration. Furthermore, a number 
of unwanted side-effects including dyskinesia and psy-
chosis are observed, in particular following prolonged ad-
ministration of L-dopa. The disadvantages of current 
therapeutic approaches require the development of alter-
native forms of treatment. 
Dopamine has been shown in recent animal studies to be 
of less importance in the regulation of psychomotor func-
tions than was previously believed. For example, a pro-
nounced locomotor stimulation can be produced in mice 
depleted of monoaminergic stores following suppression 
of glutamatergic neurotransmission (Carlsson and Carls-
son 1989a, 1989b). This finding raises the question 
whether glutamate antagonists may be of benefit in the 
treatment of Parkinson's disease. 
2. Glutamate antagonists and the therapy 
of Parkinson's disease 
There is increasing evidence that the dopaminergic nigro-
striatal system and the strio-nigral y-aminobutyric acid 
(GABA)/substance P system are only one part of a motor 
loop system which is formed by the basal ganglia and the 
motor thalamus and receives information from wide cor-
tical areas and projects to distinct premotor cortical areas 
(Albin et al. 1989). The degeneration of the dopaminergic 
nigro-striatal pathway in Parkinson's disease results in 
profound changes within this motor loop. Enhanced glu-
tamatergic activity is assumed to occur in the subthal-
amic nucleus due to a decreased GABAergic input from 
the lateral globus pallidus. Hyperactivity of the gluta-
matergic projection neurones in the subthalamic nucleus 
enhances activity in the basal ganglia output nuclei, i.e. 
the substantia nigra pars reticulata and the internal seg-
ment of the globus pallidus. The consequence of these 
alterations is a pathological degree of tonic activity in the 
basal ganglia output system directed to the motor thala-
mus and brainstem (Albin et al. 1989). This simplified 
model of basal ganglia pathophysiology in Parkinson's 
disease suggests that antiglutamatergic drugs may be of 
therapeutic benefit (Klockgether and Turski 1989). 
The validity of the concept of glutamatergic hyperactivity 
in Parkinson's disease and the potential for antigluta-
matergic therapy are underlined by studies with rodents 
demonstrating that dizocilpine, a non-competitive antag-
onist at the N-methyl-D-aspartate (NMDA) receptor sub-
type of the glutamate receptor, stimulates locomotor ac-
tivity in monoamine-depleted mice (Carlsson and Carls-
son 1989a) and rats (Klockgether and Turski 1990) and 
reverses neuroleptic-induced catalepsy in rats (Schmidt 
and Bubser 1989, Mehta and Ticku 1990). In monkeys 
rendered parkinsonian with M P T P (l-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) both the competitive N M D A 
receptor antagonist CPP ((±)-2-carboxypiperazine-4-yl-
propyl-l-phosphonic acid) and the quisqualate receptor 
antagonist N B Q X (6-nitro-7-sulphamobenzo[fJquinoxa-
line-2,3-dione) increase locomotor activity when admin-
istered with a threshold dose of L-DOPA (Loschmann et 
al. 1991). 
The only antiglutamatergic drugs available for the treat-
ment of Parkinson's disease are the non-competitive 
N M D A receptor antagonists amantadine and memantine 
(Kornhuber et al. 1991), which have moderate antiaki-
netic efficacy compared to dopamimetic substances. The 
action of memantine at the N M D A receptor might well 
explain its antiparkinsonian activity, since the K; value 
of memantine at the PCP binding site of the N M D A re-
ceptor is lower than the brain concentration reached in 
the treatment of Parkinson's disease (Kornhuber et al. 
1991, Wesemann et al. 1980). The finding that the K, 
value of amantadine is about 20 times lower than that of 
memantine is in agreement with the clinical experience 
that the mean daily dose of amantadine in the treatment 
of Parkinson's disease is about 5—10 times higher than 
that of memantine. 
Decreased glutamatergic function has been postulated to 
be a significant factor in the pathophysiology of schizo-
phrenia (Kim et al. 1980, Kornhuber et al. 1989, 1990; 
see below). Antiglutamatergic treatment of Parkinson's 
diesease carries therefore the risk of psychotic side-ef-
fects. Amantadine is known to have mild antiakinetic ef-
fects in parkinsonian patients and psychosis is a frequent 
adverse reaction (Danielczyk 1980). The occurrence of 
pharmacotoxic psychosis has been examined following 
administration of memantine in patients with Parkin-
son's disease (Table 1). Four parkinsonian subjects re-
ceived memantine in addition to their usual antiparkin-
sonian medication. Only one patient showed a mild im-
provement of his motor symptoms. The other three pa-
tients did not benefit from additional memantine admin-
istration. In two out of these three, however, memantine 
produced psychosis. Memantine administered in doses 
producing little or no antiparkinsonian effects appears to 
be likely to cause pharmacotoxic psychosis. 
In Parkinson's disease there is a lack of data confirming 
a disturbance of glutamatergic function in limbic and cor-
tical areas and supporting a glutamatergic hypothesis of 
pharmacotoxic psychosis. However, the fact that meman-
Table 1: Clinical effects of memantine in patients with Parkinson's disease. 
Patient M . G . J. S. H . E. H . P. 
Age 84 64 66 87 
Sex female male male female 
Duration of 
12 disease (years) 6 7 3 
Hoehn & Yahr 
stage3 > i v - v I V - V I V - V I V - V 
Basic therapy L-dopa(150). L-dopa (50), procycli- amantadine 
(daily dose in amantadine amantadine dine(7.5) sulfate (100), 
mg) sulfate (200), sulfate (300), terguride 
terguride terguride (1.5) 
(1.5) (0.75) 
Additional daily 30 mg for 3 20 mg for 1 10 mg for 6 10 mg for 2 
dose of meman- weeks week weeks weeks 
tine 
Clinical effect of mild impro- no improve- no impro- no improve-
memantine vement of ment of mo- vement of ment of mo-
motor symp- tor symp- motor tor symp-
toms toms, phar- symptoms toms, phar-
macotoxic macotoxic 
psychosis psychosis 
Motor score 
— Prior to me-
mantine 
administra-
tion 80 70 80 85 
— Following me-
mantine 
administra-
tion 60 70 80 85 
Psychosis Score 
— Prior to me-
mantine 
administra-
0 tion 0 0 0 
— Following me-
mantine 
administra-
tion 0 2 0 1 
The improvement of motor symptoms was rated according to a modified 
Webster scale (Webster 1968, Birkmayer and Neumayer 1972) composed 
of 10 items with scores ranging from 0 (normal function) and 10 (total 
incapacitation). 
The degree of pharmacotoxic psychosis was rated according to Moskowitz 
(1978): stage 1 = insomnia, vivid dreams, stage 2 = hallucinations, paranoid 
ideation, stage 3 = delirium, confusion. 
a ) The stage of Parkinson's disease was rated according to Hoehn and Yahr 
(1967): I = unilateral disease, II = bilateral disease without impairment of 
balance, III = bilateral disease with some postural instability, IV = severe 
disability, V = wheelchair bound or bedridden unless aided. 
tine has a considerable potential to induce pharmaco-
toxic psychosis at threshold doses which produce minor 
antiakinetic effects, may suggest that glutamatergic activ-
ity in areas responsible fur psychosis is reduced. Since 
under-active glutamatergic systems may be further inhib-
ited by N M D A receptor antagonists, psychotic side-ef-
fects are likely to occur. 
3. Glutamatergic systems in schizophrenia 
Research into the function of L-glutamate in the central 
nervous system has led to the hypothesis that decreased 
glutamatergic neurotransmission may play a role in the 
pathophysiology of psychosis (Kim et al. 1980, Korn-
huber et al. 1989, 1990). An important contribution to 
this hypothesis is the observation that the psychotomi-
metic compound phencyclidine acts at the N M D A recep-
tor subtype of the receptors activated by glutamate (An is 
et al. 1983). The psychosis evoked by phencyclidine is 
regarded to be the best current pharmacological model of 
schizophrenia (Allen and Young 1978, Snyder 1980) be-
cause this drug produces both productive psychotic 
symptoms and negative symptoms (Petersen and Still-
man 1978). It has been reported that phencyclidine 
blocks responses of central neurones to N M D A (Anis et 
al. 1983) and it has become increasingly clear that phen-
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cyclidine acts as an open channel blocker of the N M D A 
receptor-coupled ion channel (Foster and Fagg 1987) and 
is a non-competitive glutamate antagonist. 
Despite the psychotomimetic actions of phencyclidine 
and related substances in humans, data supporting the 
hypothesis of decreased glutamatergic function in schiz-
ophrenia is limited. Markers for glutamatergic neuro-
transmission are particularly high in brain areas thought 
to be involved in the pathogenesis of schizophrenia such 
as the entorhinal region, frontal cortex and hippocampus 
(Fagg and Foster 1983). Developmental disturbances of 
the second neuronal layer of the entorhinal region has 
been found in schizophrenic patients (Jakob and Beck-
mann 1986) suggesting a dysfunction of the glutamatergic 
perforant pathway. 
A decreased release of glutamate has been observed in 
the frontal and temporal cortex of schizophrenic patients 
(Sherman et al. 1991) while increased N M D A receptor 
density has been measured in the temporal and parietal 
cortex (Suga et al. 1990). In the putamen, increased 
(Kornhuber et al. 1989) and unaltered (Suga et al. 1990, 
Weissmann et al. 1991) N M D A receptor densities have 
been reported. With regard to the other glutamate recep-
tor subtypes, unchanged quisqualate receptor densities 
have been found in the frontal, temporal and parietal cor-
tex (Kurumaji et al. 1990) while kainate receptor binding 
is increased in the frontal cortex (Deakin et al. 1989, N i -
shikawa et al. 1983) and unchanged (Deakin et al. 1989) 
or decreased (Kerwin et al. 1988, Harrison et al. 1991) in 
the hippocampus. The total biochemical data available is 
of value only as a starting point for further research since 
both the number of studies and the number of the brain 
regions examined are limited. For example, the most vul-
nerable brain regions in schizophrenia, the entorhinal 
cortex (Jakob and Beckmann 1986) and the prefrontal 
cortex (Benes et al. 1986) have not been studied in detail 
and only preliminary biochemical evidence exists to sug-
gest that N M D A receptor density is marginally increased 
in the entorhinal cortex (Kornhuber et al. 1989). 
4. The glutamatergic-dopaminergic link 
in schizophrenia 
Of the hypotheses put forward to explain the biochemical 
basis of schizophrenia and in particular paranoid hallu-
cinatory symptoms, the dopamine hypothesis has been 
the most influential. The dopamine hypothesis of schiz-
ophrenia is based mainly on indirect pharmacological ob-
servations. The biochemical data available, however, in-
dicate that there may be no absolute dopaminergic hy-
peractivity in the brain (Kornhuber et al. 1990). The bio-
chemical abnormality in schizophrenia may well be lo-
cated in another neurotransmitter system which is 
somehow linked to dopaminergic neurones. The dopa-
minergic and glutamatergic systems are closely linked to 
one another, thus possibly explaining the therapeutic ac-
tion of neuroleptic drugs (Kim et al. 1980). Dopamine 
functionally antagonizes the glutamatergic system. For 
example, activation of the dopaminergic system reduces 
glutamate release from cortico-striatal terminals while 
neuroleptic drugs reactivate the glutamate release (Korn-
huber and Kornhuber 1986). 
The glutamate hypothesis of schizophrenia unifies the 
structural alterations found in the cerebral cortex in 
schizophrenic patients, the psychotomimetic effects of 
phencyclidine and the therapeutic activity of dopamine 
antagonists in the treatment of schizophrenia. 
5. Conclusion 
The importance of a central dopaminergic-glutamatergic 
balance in akinesia and psychosis is summarized in Fig. 
Response 
Anri-akineric 
induction of psychosis 
Dopamimetics 
L-Dopa 
Bromocriptine 
Lisuride 
L-Deprenyl 
Anticholinergics 
Response 
Anti-kinetic 
improvement of psychosis ? 
Balance 
Glutamate 
agonists parf.agonists 
Glutamate antagonists 
non-
competitive competitive 
Dopamine dizocilpine CPP 
antagonists PCP AP5 
Neuroleptics Amantadine 
"<J^  "s/ Memantine 
Anti-kinetic Anti-akinetic 
improvement of psychosis induction of psychosis 
Fig. 1: Simplified illustration of glutamatergic and dopaminergic balances 
in the brain: importance in akinesia and schizophrenia. PCP = phencycli-
dine, CPP = (±)-2-carboxypiperazine-4-y l -propyl - l -phosphomc acid, AP5 
= 2-amino-5-phosphonopentanoic acid. 
1. An increase of dopaminergic activity and/or a reduc-
tion of glutamatergic activity may contribute to the de-
velopment of paranoid hallucinatory psychosis in schiz-
ophrenic patients and of pharmacotoxic psychosis in Par-
kinson's disease. Both dopamine antagonists and gluta-
mate agonists should therefore be of therapeutic benefit 
in these conditions. By contrast, a loss of dopaminergic 
activity or glutamatergic hyperactivity may result in ak-
inesia. According to this assumption dopamimetic com-
pounds as well as glutamate antagonists should have anti-
akinetic properties. 
The possible efficacy of N M D A antagonists in Parkin-
son's disease could be a useful addition to the established 
dopamimetic therapy. It is well known that all dopami-
metic substances cause pharmacotoxic psychosis in Par-
kinson's disease and are able to aggravate productive 
symptoms in schizophrenia. It is not known, however, 
whether competitive N M D A receptor antagonists, which 
are known to enhance locomotor activity in animal mod-
els of Parkinson's disease (Svensson et al. 1991, Losch-
mann et al. 1991), have potent antiakinetic efficacy in 
Parkinson's diesease or whether these substances also 
create the adverse reactions of dopamimetics and non-
competitive N M D A receptor antagonists. 
Further biochemical, pharmacological and clinical evi-
dence is required in order to provide a clearer under-
standing of the biological alterations underlying psy-
chotic disturbances. Assuming that glutamate plays a cru-
cial role in schizophrenia, new therapeutic strategies in-
volving the N M D A receptor-ionophore complex should 
be developed. Enhancement of the glutamatergic tone in 
the brain for the treatment of schizophrenia may produce 
neurotoxic and convulsive side-effects (Meldrum and 
Garthwaite 1990). 
Because of possibly severe side-effects of glutamatergic 
agonists and antagonists in the treatment of akinesia and 
psychosis, the development of partial glutamate agonists/ 
antagonists could be an alternative strategy capable of 
producing anti-psychotic or anti-kinetic effects with only 
mild adverse reactions. 
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Dopaminergic and Serotonergic Effects of Clozapine 
Implications for a unique clinical profile 
H . Y. Meltzer and G. A. Gudelsky 
Summary 
The clinical profile of clozapine (CAS 5786-21-0) is char-
acterized by superior efficacy in reducing the positive and 
negative symptoms of schizophrenia and a greatly reduced 
propensity to elicit acute extrapyramidal symptoms (e.g., 
Parkinsonian symptoms), long-term effects (e.g., tardive 
dyskinesia) and hyper prolactinemia. For these reasons clo-
zapine is considered the prototypic atypical antipsychotic. 
The failure of clozapine to elevate serum prolactin con-
centrations may be related to the stimulatory effect of do-
Department of Psychiatry, Case Western Reserve University, 
School of Medicine, Cleveland, Ohio (USA) 
zapine on tuberoinfundibular dopamine neurons and/or 
the failure of clozapine to achieve effective blockade of 
pituitary dopamine D2 receptors. The lack of acute block-
ade of striatal D2 receptors by clozapine and the failure 
of chronic clozapine treatment to suppress striatal dopa-
mine release, relative to that produced by typical anti-
psychotic agents, may account for the lack of acute extra-
pyramidal symptoms* and tardive dyskinesia, respectively, 
associated with the use of clozapine. Although the neu-
rochemical substrates that subserve the unique preclinical 
and clinical profile of clozapine have not been determined 
unequivocally, clozapine and other purported atypical an-
tipsychotic agents produce a greater antagonism of5-HT2 
receptors relative to D2 receptors than is the case for typical 
antipsychotics. Clozapine also exerts antagonism of 
D, receptors. It is proposed that the selective interaction 
of clozapine among D2, Dh D4 and 5-HT2 receptors results 
in a distinctive alteration in the function of pre- and post-
synaptic dopamine elements. 
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